2015

Hormonal Prostate Cancer Treatment May Double the Risk of Alzheimer’s Disease.

A recent study published in the Journal of Clinical Oncology comprising a large-scale analysis of medical records revealed that men undergoing androgen deprivation (hormonal) therapy (ADT) for prostate cancer treatment may be at almost twice the risk of eventually developing Alzheimer’s disease, and that the increased likelihood of the disease is proportional to ADT duration.  The researchers emphasized more »

Prostate Cancer Patients Undergoing Active Surveillance Are Not Receiving the Proper Follow-Up.

A recent study from UCLA published in the December 1st issue of Cancer, included 3,600 men who had opted for active surveillance in place of aggressive treatment as a means of following the status of their prostate cancer.  The study found that only 4.5% received proper monitoring in collaboration with their physician.  Recommended monitoring includes regular more »

Cancer Patients Should Avoid Taking Antioxidant Supplements.

The following November 12th, 2015 article comes from the National Cancer Institute (NCI), the largest institute of the National Institutes of Health (NIH).  Antioxidants are often advertised to prevent the types of free radical damage that have been associated with cancer development.  Multiple large, placebo-controlled, prevention clinical trials have never confirmed this hypothesis.  Instead, evidence more »

Ovarian and Breast Cancer Drug, Olaparib, is Effective in a Significant Number of Men with Advanced Prostate Cancer.

A major trial has concluded that a pioneering drug from AstraZeneca, olaparib, developed to treat women with inherited cancers, can also benefit men with certain types of advanced prostate cancer.  Olaparib inhibits the enzyme, poly (ADP ribose) polymerase (PARP), a protein used by cancer cells to carry out DNA repairs.  PARP inhibitors work on cancers more »

Information on Prostate Supplements and PSA Testing

The Prostate Cancer Foundation (PCF) publishes a highly recommended e mail periodical entitled NewsPulse to which one can subscribe.  The October issue contained two articles which I will simply summarize and link. The first article concluded that popular prostate supplements such as those containing saw palmetto do not benefit prostate cancer patients.  They do not more »

Don’t Let Yourself Go! The Benefits of Exercise During Hormone Therapy

A recent article written by researchers from the University of Southern California was published in the August 2015 issue of Prostate Insights from the Prostate Cancer Research Institute.  The article discussed how exercise may help with treatment-related side effects of hormone therapy (ADT) and what types of exercise were most effective.  Two of the primary more »

AR-V7: A Genetic Test to Determine Effectiveness of Enzalutamide and Abiraterone.

When prostate cancer becomes “hormone resistant” or refractory, anti-androgen drugs such as enzalutamide (Xtandi®) and abiraterone (Zytiga®) are often prescribed.  But not all patients respond equally. Some 30 percent of men with advanced prostate cancer have an abnormal version of a prostate cancer protein that connects with testosterone.  The protein is missing a key connector more »

Taking Charge of Your Prostate Cancer Recovery; Old Model Revised.

The following is from the October 7th Prostatesnatchers, as written by Ralph Blum and urinary oncologist, Dr. Mark Scholz.  I urge the readers to subscribe to their periodic e mail posts. In the old model of prostate cancer care, you were rushed into radical treatment–usually surgery or radiation–often without fully understanding all your options, or the more »

Earlier chemotherapy may extend patient survival in multiple prostate cancer settings

Whether a prostate cancer patient is just presenting with localized high risk prostate cancer, presenting with metastatic prostate cancer, or experiencing a metastatic recurrence, earlier treatment with taxane chemotherapy may prolong survival. June 19, 2015 — Chemotherapy with docetaxel® (taxotere) has traditionally been used to treat prostate cancer patients only after they have developed resistance more »

Men With Low-Risk Prostate Cancer In Active Surveillance Program Not Likely To Succomb To The Disease, Study Shows.

The post below comes from a multi-year study at Johns Hopkins in Baltimore. It should be noted below that repeat biopsies performed on men undergoing active surveillance were performed using MRI-guided technology and pathologists checked biopsy tissue levels of proteins made by the PTEN gene, a biomarker for prostate cancer aggressiveness. Men with relatively unaggressive more »

More Evidence for the Positive Effect of Statins and Metformin in High-Risk Prostate Cancer.

A total of 22,110 high-risk prostate cancer patients were evaluated of which 1,365 died of prostate cancer.  The study authors concluded that the use of a statin medication in combination with metformin was associated with a 43% reduction in prostate cancer mortality.  The benefit was present in all men but was present to a larger more »

Stereotactic Body Radiation (SBRT) and CyberKnife in the Treatment of Prostate Cancer

Stereotactic Body Radiation (SBRT) accurately delivers very high doses of external radiation beams to the whole prostate gland thereby treating the tumor within while minimizing extra-prostactic radiation exposure to the adjacent normal tissues.  Because SBRT delivers a much higher dose of radiation during each treatment visit, the overall treatment time is sharply reduced. Generally a more »

Radiation Cystitis – An Undesirable Potential Side Effect of Radiation Therapy

I was recently made aware of an unexpected, undesirable side effect of prostate cancer radiation therapy called radiation cystitis which first occurred more than ten years after radiation treatment.  This can be caused by the incidental irradiation of the bladder during radiation therapy for prostate cancer.  Radiation cystitis is  characterized by blood in the urine more »